SCHEDULE 13G/A: BlackRock Amends Biogen Stake Disclosure, Reports 8.5% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 8.5% of Biogen Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 16 to Schedule 13G regarding its beneficial ownership in Biogen Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 12,506,681 shares of Biogen Inc. common stock.
- This represents 8.5% of the total outstanding common shares of Biogen Inc.
- BlackRock, Inc. holds sole voting power over 11,125,519 shares.
- BlackRock, Inc. holds sole dispositive power over 12,506,681 shares.
- No shared voting or dispositive power was reported.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Biogen Inc.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, regarding its passive investment stake in a publicly traded biotechnology company, Biogen Inc. Such filings are standard for investors holding more than 5% of a company's shares and do not typically indicate a change in industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement (reporting period end). |
| 2025-04-17 | Date of filing of this Schedule 13G Amendment No. 16. |
Keywords
BlackRock, Biogen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.